ERBB4 and breast cancer: PF-00299804 is an orally active pan-HER tyrosine kinase inhibitor which specifically and irreversibly binds to and inhibits HER1, HER2 and HER4 which was evaluated in non-small cell lung cancer patients at ASCO 2008 but also exhibits potential activity in HER2 positive breast cancer patients.[67]